On July 8, 2024, Yuhui, Member of the Standing Committee of the Xihu District Committee and Deputy District Mayor, together with Shen Qinhua, Founding Managing Partner of Puhua Capital, visited Sinboda for an inspection and research tour. Hu Xianyan, Marketing Director of Sinboda, accompanied the delegation.
Deputy District Mayor Yuhui and Ms. Shen Qinhua listened to a presentation by Hu Xianyan covering the company's overview, development history, technology platforms, application fields, and future expansion plans. They gained in-depth insights into the company's four major technology platforms spanning life sciences and clinical applications across the full process:
Single-Molecule Conformation Immunoassay Platform: Sinboda's pioneering immunoassay in-vitro diagnostic platform based on single-molecule imaging, enabling combined characterization of target protein concentration and morphological information, providing an ideal solution for blood-based detection of neurodegenerative diseases such as Alzheimer's and Parkinson's.
Single-Cell Micro-Nano Manipulation Platform: Sinboda's pioneering automated in-situ cell manipulation platform, enabling efficient and non-destructive cell isolation, extraction, and intracellular injection, offering a revolutionary universal technology for industries such as cell therapy, gene editing, and prenatal diagnosis.
Microscopy Imaging Platform: A self-developed single-lens 3D light-sheet microscope capable of high-resolution real-time dynamic recording of living cells, delivering groundbreaking value for cell therapy.
AI-Powered Healthcare: R&D pipeline products based on intelligent instrumentation and big-data algorithms, including mixed reality (MR) intraoperative navigation, movement disorder rehabilitation instruments based on multimodal human behavior understanding, and macro-micro interactive section scanners. The synergistic development of these four technology platforms collectively demonstrates Sinboda's outstanding strength under an innovation-driven development strategy.
Deputy District Mayor Yuhui expressed high appreciation for Sinboda's achievements in biomedical innovation technologies. He noted that the company's core technological advantages and innovative outcomes not only fill domestic gaps but also have the potential to break import monopolies and lead industry transformation. He emphasized that the government will continue to support technology-innovative enterprises through policy support, resource matching, and other measures, creating a more favorable development environment and conditions for enterprises.
Finally, Hu Xianyan, Marketing Director, expressed sincere gratitude on behalf of Sinboda to the Xihu District Government for its ongoing care, support, and assistance. Sinboda will live up to the government's expectations, continuing to develop globally leading life and health technology platforms, providing advanced instruments and solutions for medical and research purposes, safeguarding lives, improving quality of life, and achieving infinite possibilities for life and health through technological innovation.